Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204

Executive Summary

• The Japan Patent Office granted Japanese Patent No. 2022‑554855 to Marvel Biosciences for its lead therapeutic candidate MB‑204, covering composition‑of‑matter and method‑of‑use claims.
• This is the second major jurisdiction to issue a composition‑of‑matter patent for MB‑204, strengthening Marvel’s global IP portfolio and supporting future clinical development and partnership opportunities.
• MB‑204 has completed preclinical toxicology testing, demonstrated improved pharmacokinetics versus Istradefylline, and shown efficacy in multiple autism‑related animal models, including Rett syndrome and ongoing studies in Fragile X syndrome.

Key Details

• Patent Information: Japanese Patent No. 2022‑554855 titled “Purine Compounds for Treating Disorders”; covers composition of matter and methods of use for MB‑204.
• Candidate Overview: MB‑204 is a novel fluorinated analogue of Istradefylline (an approved adenosine A₂A receptor antagonist).
• Preclinical Milestones:
• Completed preclinical toxicology testing.
• Demonstrated improved pharmacokinetic profile relative to parent compound.
• Showed robust efficacy in depression models and multiple autism models, including Rett syndrome; currently being evaluated in Fragile X syndrome models.
• Strategic Impact: Securing patent protection in Japan enhances Marvel’s global IP coverage, potentially increasing the long‑term value of MB‑204 and facilitating strategic partnership or licensing discussions.
• Market Context: Autism spectrum disorder affects ~1 in 36 children by age eight, highlighting unmet therapeutic needs that MB‑204 aims to address.

Notable Quotes

“This represents the second major jurisdiction to grant a composition‑of‑matter patent for our lead molecule MB‑204,” said Rod Matheson, CEO of Marvel Biosciences.
“Securing patent protection in Japan significantly strengthens our global intellectual property portfolio and further enhances the long‑term value of MB‑204 as we advance toward clinical development.”